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Abstract
Background: The Meta-Analysis of Glucose and Insulin related traits Consortium (MAGIC) recently identified 16 loci robustly
associated with fasting glucose, some of which were also associated with type 2 diabetes. The purpose of our study was to
explore the role of these variants in South Asian populations of Punjabi ancestry, originating predominantly from the
District of Mirpur, Pakistan.
Methodology/Principal Findings: Sixteen single nucleotide polymorphisms (SNPs) were genotyped in 1678 subjects with
type 2 diabetes and 1584 normoglycaemic controls from two Punjabi populations; one resident in the UK and one
indigenous to the District of Mirpur. In the normoglycaemic controls investigated for fasting glucose associations, 12 of 16
SNPs displayed b values with the same direction of effect as that seen in European studies, although only the SLC30A8
rs11558471 SNP was nominally associated with fasting glucose (b=0.063 [95% CI: 0.013, 0.113] p=0.015). Of interest, the
MTNR1B rs10830963 SNP displayed a negative b value for fasting glucose in our study; this effect size was significantly lower
than that seen in Europeans (p=1.29610
24). In addition to previously reported type 2 diabetes risk variants in TCF7L2 and
SLC30A8, SNPs in ADCY5 (rs11708067) and GLIS3 (rs7034200) displayed evidence for association with type 2 diabetes, with
odds ratios of 1.23 (95% CI: 1.09, 1.39; p=9.1610
24) and 1.16 (95% CI: 1.05, 1.29; p=3.49610
23) respectively.
Conclusions/Significance: Although only the SLC30A8 rs11558471 SNP was nominally associated with fasting glucose in our
study, the finding that 12 out of 16 SNPs displayed a direction of effect consistent with European studies suggests that a
number of these variants may contribute to fasting glucose variation in individuals of South Asian ancestry. We also provide
evidence for the first time in South Asians that alleles of SNPs in GLIS3 and ADCY5 may confer risk of type 2 diabetes.
Citation: Rees SD, Hydrie MZI, O’Hare JP, Kumar S, Shera AS, et al. (2011) Effects of 16 Genetic Variants on Fasting Glucose and Type 2 Diabetes in South Asians:
ADCY5 and GLIS3 Variants May Predispose to Type 2 Diabetes. PLoS ONE 6(9): e24710. doi:10.1371/journal.pone.0024710
Editor: Nicholas John Timpson, University of Bristol, United Kingdom
Received May 11, 2011; Accepted August 17, 2011; Published September 20, 2011
Copyright:  2011 Rees et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for the collection of DNA and clinical data from the Pakistan-resident population (DGP) was provided by Diabetes UK (project number 07/
0003512; www.diabetes.org.uk). Funding for genetic analyses was provided by Eli Lilly. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have the following competing interests: This study was partly funded by Eli Lilly. Prof. Sudhesh Kumar has received lecture
fees and research funding from Eli Lilly. Prof. Anthony Barnett has received honoraria from Eli Lilly for lectures and advisory work, and has received research
funding from Eli Lilly. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS
ONE policies on sharing data and materials.
* E-mail: s.d.rees@bham.ac.uk
Introduction
Type 2 diabetes, a disease that is 4- to 6-fold more common in
South Asian individuals than Europeans, is characterised by
impaired glucose homeostasis resulting from a combination of beta
cell dysfunction and insulin resistance. This inability to adequately
regulate blood glucose levels is also linked to both micro- and
macro-vascular complications. Recently, the Meta-Analysis of
Glucose and Insulin related traits Consortium (MAGIC) identified
16 genetic variants robustly associated with fasting glucose in non-
diabetic populations of European origin [1]. Although a number of
these single nucleotide polymorphisms (SNPs) were also associated
with type 2 diabetes, several were not, suggesting that some variants
may be associated with a ‘physiological’ variation in glucose levels
without influencing ‘pathological’ variation and type 2 diabetes risk
[1]. As with other genetic associations, replication of these findings
in datasets of different ethnic origin is an important step in helping
to fine-map the aetiological variants at these loci. Our aim was to
investigate the effect of these 16 SNPs on fasting glucose levels and
type 2 diabetes in South Asian populations of Punjabi ancestry.
Materials and Methods
Ethics statement
Informed written consent was obtained from all study
participants and the studies were approved by the Birmingham
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24710East, North and Solihull Research Ethics Committee (UKADS
participants) and the Baqai Institute of Diabetology and
Endocrinology Institutional Review Board (DGP participants).
UKADS registered clinical trial number; ISRCTN38297969.
Study design
Participants in the investigation (Table 1) were from two studies
of South Asian individuals; the United Kingdom Asian Diabetes
Study (UKADS; 857 participants with type 2 diabetes, 417 without)
[2,3] and the Diabetes Genetics in Pakistan study (DGP; 821
participants with type 2 diabetes, 1167 without) [3]. Participants
were all of Punjabi ancestry, confirmed over three generations, and
originated predominantly from the District of Mirpur, Pakistan.
Diagnosis of type 2 diabetes was established using World Health
Organisation criteria [4]. Normoglycaemic control subjects were
recruited from the same geographical region as subjects with type 2
diabetes. In the UKADS control group normal glucose tolerance
was defined in the majority of participants as random blood glucose
,7 mmol/l. In a small number of UKADS controls (n=22),
normoglycaemia was defined as fasting plasma glucose
,6.1 mmol/l and 2 hr plasma glucose ,7.8 mmol/l on a 75 g
OGTT; due to small sample size these data were not included in
any fasting glucose analyses. Normal glucose tolerance in the DGP
control group was defined as fasting whole blood glucose
#5.6 mmol/l. Genomic DNA was extracted either from venous
blood using the NucleonH protocol (Nucleon Biosciences, Coat-
bridge, UK) (UKADS) or from saliva using the OrageneH DNA
sample collection kit and extraction protocol (DNA Genotek Inc.,
Ontario,Canada)(DGP).Theclinical detailsofindividuals from the
two study populations are shown in Table 1.
Genotyping
All subjects (UKADS, n=1274; DGP, n=1988; total, n=3262)
were genotyped for the 16 SNPs using the KASPar method
(KBioscience, Hoddesdon, UK). Genotyping success rates were
.96% for each SNP. Approximately 10% of samples were genotyped
as blind duplicates resulting in an error rate of ,1% for each SNP.
Genotype counts in the two study populations are shown in Table S1.
Statistical analyses
Deviation from Hardy-Weinberg equilibrium (HWE) in the
non-diabetic groups was tested using an exact test implemented in
Haploview [5]. None of the SNPs deviated significantly from
Table 1. Demographic and health characteristics of study
participants in the two populations.
UKADS DGP
Controls T2D cases Controls T2D cases
n (male/female) 217/200 388/469 617/550 430/391
Age (years) 54.9 (11.7) 56.9 (12.0) 56.3 (10.8) 54.6 (11.7)
Fasting plasma glucose
(mmol/l)
225.5 (0.6) 2
Random blood glucose
(mmol/l)
5.3 (0.9) 222
HbA1c (%) 2 8.3 (1.9) 2 9.6 (3.2)
BMI (kg/m
2) 28.0 (4.9) 28.6 (4.6) 24.3 (5.0) 26.1 (4.7)
All values except (n) are means (SD). T2D=type 2 diabetes. Within the UKADS
control group BMI data were only available for 256 subjects.
doi:10.1371/journal.pone.0024710.t001
Table 2. Association of SNPs with type 2 diabetes in the UKADS and DGP study populations.
UKADS DGP UKADS/DGP
Nearest
gene SNP
Allele
(Risk/
other) RAF OR (95% CI) p RAF OR (95% CI) p RAF OR (95% CI) p
Heterogeneity
p
MTNR1B rs10830963 G/C 0.42 0.93 (0.79, 1.10) 0.403 0.39 0.99 (0.88, 1.13) 0.92 0.40 0.97 (0.88, 1.07) 0.558 0.544
ADRA2A rs10885122 G/T 0.79 0.94 (0.76, 1.15) 0.525 0.75 1.13 (0.98, 1.32) 0.10 0.76 1.06 (0.94, 1.20) 0.339 0.138
C2CD4B rs11071657 A/G 0.70 0.93 (0.77, 1.12) 0.458 0.68 0.92 (0.80, 1.05) 0.21 0.68 0.92 (0.83, 1.03) 0.147 0.899
SLC30A8 rs11558471 C/T 0.71 1.11 (0.93, 1.34) 0.242 0.74 1.14 (0.99, 1.33) 0.07 0.73 1.13 (1.01, 1.27) 0.034 0.827
CRY2 rs11605924 A/C 0.48 1.14 (0.96, 1.35) 0.143 0.49 0.94 (0.82, 1.06) 0.30 0.49 1.00 (0.91, 1.11) 0.974 0.072
ADCY5 rs11708067 A/G 0.74 1.26 (1.04, 1.54) 0.019 0.77 1.21 (1.03, 1.41) 0.02 0.76 1.23 (1.09, 1.39) 0.001 0.715
SLC2A2 rs11920090 T/A 0.85 1.13 (0.89, 1.43) 0.325 0.85 0.94 (0.78, 1.12) 0.47 0.85 1.00 (0.87, 1.15) 0.997 0.222
FADS1 rs174550 T/C 0.81 1.02 (0.82, 1.26) 0.869 0.81 1.19 (1.00, 1.41) 0.05 0.81 1.12 (0.98, 1.28) 0.095 0.264
GCK rs1799884 A/G 0.16 0.79 (0.62, 1.00) 0.047 0.15 1.05 (0.88, 1.25) 0.58 0.15 0.95 (0.82, 1.09) 0.461 0.055
DGK/TMEM195 rs2191349 T/G 0.62 0.93 (0.78, 1.11) 0.418 0.60 1.16 (1.02, 1.32) 0.02 0.60 1.07 (0.97, 1.19) 0.179 0.044
PROX1 rs340874 C/T 0.59 1.00 (0.84, 1.18) 0.956 0.59 0.97 (0.85, 1.10) 0.60 0.59 0.98 (0.88, 1.08) 0.656 0.787
G6PC2 rs560887 C/T 0.82 1.22 (0.97, 1.53) 0.084 0.84 0.89 (0.75, 1.06) 0.19 0.84 1.00 (0.87, 1.14) 0.993 0.030
GLIS3 rs7034200 A/C 0.48 1.14 (0.96, 1.35) 0.133 0.48 1.18 (1.04, 1.34) 0.01 0.48 1.16 (1.05, 1.29) 0.003 0.748
GCKR rs780094 C/T 0.74 0.87 (0.72, 1.05) 0.139 0.72 1.07 (0.93, 1.23) 0.35 0.73 0.99 (0.89, 1.11) 0.883 0.081
TCF7L2 rs7903146 T/C 0.31 1.25 (1.05, 1.49) 0.014 0.32 1.22 (1.07, 1.40) 0.00 0.32 1.23 (1.11, 1.37) 0.000 0.870
MADD rs7944584 A/T 0.77 1.01 (0.83, 1.23) 0.893 0.78 1.12 (0.96, 1.31) 0.15 0.78 1.08 (0.95, 1.22) 0.230 0.436
UKADS=UK Asian Diabetes Study; DGP=Diabetes Genetics in Pakistan; Risk allele is the fasting glucose raising allele reported in Dupuis et al [1]; RAF=risk allele
frequency, calculated using the normoglycaemic control groups.
The GCK rs1799884 SNP was used as a proxy for the rs4607517 variant reported in Dupuis et al [1] (r
2=1.0 in CEU HapMap samples).
doi:10.1371/journal.pone.0024710.t002
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used to test for association between SNPs and fasting glucose levels
in the DGP control group only, adjusting for age, sex and BMI.
Four DGP control participants had missing BMI data; the sample
size for the fasting glucose analysis was therefore 1163. Fasting
plasma glucose estimates were calculated from fasting whole blood
measurements using a conversion factor of 1.15. Association
between SNPs and type 2 diabetes was tested in the UKADS and
DGP study populations separately, using logistic regression,
adjusting for age and sex. Inverse variance weighted meta-
analysis, implemented in Metan, was used to combine ORs from
the UKADS and DGP study populations. Only 256 UKADS
controls had available BMI data. As BMI made little difference to
the type 2 diabetes association (combined UKADS/DGP OR
difference #0.015 for all SNPs), to maintain sample size and
power the main results are not adjusted for BMI. Heterogeneity of
ORs (between UKADS and DGP study populations, and between
the combined UKADS/DGP cohort and previously published
studies) was assessed using Cochran’s Q statistics. None of the
studied SNPs displayed significant heterogeneity of ORs between
the UKADS and DGP study populations after correcting for
multiple testing (Table 2). For all single-locus analyses in this study,
two levels of statistical significance are referred to; nominal
significance (p,0.05) and study-wide significance (p,3.13610
23,
corrected for 16 independent tests). Genetic risk scores (GRSs)
were constructed to investigate the additive effect of multiple SNPs
on fasting glucose levels and type 2 diabetes. For all GRS analyses,
only those individuals successfully genotyped at $12 SNPs
(nmax=3231) were included. Firstly an allele count GRS (acGRS)
was constructed. For each individual, the average number of risk
alleles per successfully genotyped SNP (total number of observed
risk alleles/number of successfully genotyped SNPs) was multiplied
by the total number of SNPs included in the GRS. This produced
a GRS approximating a simple risk allele count where all SNPs
were successfully genotyped. Two weighted GRSs (wGRS) were
also produced, one for the fasting glucose analyses and one for the
type 2 diabetes analyses. Risk alleles of each SNP were weighted
by a SNP-specific b-value, obtained from the MAGIC study [1],
and the weighted allele count was divided by the mean MAGIC-
derived b-value for the successfully genotyped SNPs. GRSs for the
type 2 diabetes analyses were also estimated without the TCF7L2
and SLC30A8 variants, as these SNPs have previously displayed
association with the disease in the UKADS and DGP study
populations [3,6]. All statistical analyses were performed using
Stata IC Version 10.1 (Stata Corporation, College Station, TX,
USA). Power was calculated using Genetic Power Calculator
(http://ibgwww.colorado.edu/,pshaun/gpc/) [7] and Quanto
version 1.2 (http://hydra.usc.edu/gxe) [8], assuming a signifi-
cance level (a) of 0.05.
Results
Associations with fasting glucose
Of the 16 SNPs studied, 12 displayed b-values with the same
direction of effect as that seen in Europeans, and the SLC30A8
rs11558471 variant displayed a nominally significant association
with fasting glucose levels (b=0.063 [95% CI: 0.013, 0.113]
p=0.015) (Figure 1). No evidence for heterogeneity of effect sizes
between our study and a previous study of Europeans was
apparent for 15 of the studied variants. In contrast, the MTNR1B
rs10830963 effect size was markedly lower in the current study
compared with the Europeans from the MAGIC study [1] and this
heterogeneity achieved study-wide significance (p=1.29610
24).
The acGRS showed a stronger association with fasting glucose
than did the wGRS (b=0.013 [95% CI: 0.000, 0.025] p=0.046
and b=0.007 [95% CI: 20.004, 0.018] p=0.204 respectively)
(Figure 1).
Associations with type 2 diabetes
None of the 16 studied variants displayed strong evidence for
heterogeneity of effect on type 2 diabetes risk between the current
study and the MAGIC study. In addition to the TCF7L2 and
SLC30A8 variants, which have previously demonstrated associa-
tion with type 2 diabetes in the UKADS/DGP study populations
[3,6], alleles of the ADCY5 rs11708067 (OR=1.23 [95% CI: 1.09,
1.39] p=9.10610
24) and GLIS3 rs7034200 (OR=1.16 [95% CI:
1.05, 1.29] p=3.49610
23) SNPs conferred risk of the disease in
this study (Figure 2). The strength of these associations reached
study-wide significance for the ADCY5 variant; the GLIS3 SNP
failed to reach this threshold by a narrow margin. Both risk score
measures were associated with type 2 diabetes, with the wGRS
displaying a stronger association (OR=1.04 [95% CI: 1.02, 1.06]
p=1.00610
25) than the acGRS (OR=1.05 [95% CI: 1.02, 1.08]
p=0.001) (Figure 2). The strength of association of both risk scores
was greatly attenuated by the removal of the previously associated
TCF7L2 and SLC30A8 variants (wGRS; OR=1.01 [95% CI:
0.990, 1.04] p=0.261, acGRS; OR=1.03 [95% CI: 1.00, 1.06]
p=0.071).
Discussion
In this study we investigated the effects of 16 SNPs on fasting
glucose levels and type 2 diabetes risk in two South Asian
populations of Punjabi ancestry. Only the SLC30A8 rs11558471
variant was nominally associated with fasting glucose levels.
Twelve of the 16 SNPs displayed positive b-values, however,
suggesting that a number of these variants may be true
determinants of fasting glucose levels in our study populations
(Figure 1), even though their effects were too small to be accurately
detected in our modestly-sized cohort. Comparing the effect sizes
observed in this study to those reported in Europeans highlights
some potential differences. Three of the six variants most strongly
associated with fasting glucose in the MAGIC study [1](MTNR1B
rs10830963, DGKB/TMEM195 rs2191349 and ADCY5
rs11708067) have negative b-values in the current study
(Figure 1), and this disparity reached statistical significance for
the MTNR1B variant. The observed differences in effect size are
probably the reason that the acGRS was nominally associated with
fasting glucose levels, but the wGRS (weighted using European-
derived b-values) was not.
It is of interest to note that variants within or near GCK, GCKR,
G6PC2 and MTNR1B have been shown to be associated with
fasting glucose levels in Indian Asians, with similar effect sizes to
those seen in Europeans [9]. The GCK and GCKR SNPs studied in
Indian Asians (rs4607519 and rs1260326 respectively) are in
strong linkage disequilibrium (LD) with the SNPs genotyped in this
Figure 1. Association of 16 SNPs with fasting glucose in South Asians and Europeans. South Asians from the current study (filled
diamonds, n=1163) and Europeans from the MAGIC [1] study (unfilled diamonds, n#76,558). acGRS=allele count GRS, wGRS=weighted GRS.
ES=effect size, the per-risk allele change in fasting glucose (mmol/l). The GCK rs1799884 SNP was used as a proxy for the rs4607517 variant reported
in Dupuis et al [1] (r
2=1.0 in CEU HapMap samples).
doi:10.1371/journal.pone.0024710.g001
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2$0.96 in GIH HapMap [10] samples; Gujerati Indians in
Houston, Texas) and the G6PC2 rs560887 SNP was genotyped in
both studies. The fasting glucose association results we present for
GCK and GCKR are very similar to those demonstrated in both the
Europeans from the MAGIC [1] study (Figure 1) and Indian
Asians [9]. Although our estimate of effect size for the G6PC2
rs560887 variant is low (Figure 1), it is not statistically different
from that seen in Europeans. In contrast, the MTNR1B
rs10830963 variant displayed an effect size lower than that seen
in Europeans, at study-wide significance. The MTNR1B variant
reported as being associated with fasting glucose in Indian Asians
[9] (rs2166706) is only in moderate LD (r
2=0.45) with the variant
(rs10830963) genotyped in our South Asian cohort and reported as
the sentinel MTNR1B SNP in the MAGIC study [1]; if different
LD patterns result in rs2166706 being in tighter LD with the
aetiological variant than rs10830963 in South Asians, this may
explain some of the observed discrepancy in effect size. It must be
noted, however, that this LD estimate is taken from CEU (Utah
residents with Northern and Western European ancestry from the
CEPH collection) HapMap samples as rs10830963 has not been
genotyped in the GIH HapMap samples. In addition, imputation
analyses in the Indian Asian study estimated that the strongest
association signal for fasting glucose in this population was in fact
the rs10830963 SNP [9], although this imputation was not able to
utilise South Asian-specific LD patterns. It is interesting to note
that a recent study of Indian Sikhs demonstrated that a low
frequency variant (rs1374645) was associated with glucose levels,
whereas rs10830963 was not [11]. Further studies of MTNR1B
SNPs and their association with glucose levels in South Asians may
be useful in fine-mapping the aetiological variant.
Variants in TCF7L2 and SLC30A8 have previously been
associated with type 2 diabetes in our Punjabi populations [3,6].
In addition to these variants, SNPs in ADCY5 and GLIS3 were
associated with the disease in the current study. To our knowledge,
this is the first time that either of these SNPs has been implicated
in type 2 diabetes development in a South Asian population. The
ADCY5 gene encodes adenylate cyclase 5, an enzyme that catalyses
the generation of cAMP, a second messenger vital in a number of
biological processes. It has been demonstrated in a large meta-
analysis of Europeans that the rs11708067 SNP within ADCY5 is
strongly associated (p#3.6610
28) with type 2 diabetes, fasting
glucose levels and HOMA-B (a measure of b-cell function) but is
not associated with HOMA-IR (a measure of insulin resistance)
[1,12]. This suggests that variants within this gene may exert their
Figure 2. Association of 16 SNPs with type 2 diabetes in South Asians and Europeans. South Asians from the current study (filled
diamonds, n=3262) and Europeans from the MAGIC [1] study (unfilled diamonds, n#127,667). acGRS=allele count GRS, wGRS=weighted GRS.
ES=effect size, the per-risk allele odds ratio. The GCK rs1799884 SNP was used as a proxy for the rs4607517 variant reported in Dupuis et al [1]
(r
2=1.0 in CEU HapMap samples).
doi:10.1371/journal.pone.0024710.g002
Table 3. Statistical power for fasting glucose and type 2 diabetes analyses in the combined UKADS/DGP study population.
Type 2 diabetes analyses
(n=3262)
Fasting glucose analyses
(n=1163)
Nearest gene SNP South Asian RAF MAGIC RAF
MAGIC effect size
(OR) Power
MAGIC effect size
(mmol/l) Power
MTNR1B rs10830963 0.40 0.30 1.09 0.48 0.067 0.75
ADRA2A rs10885122 0.76 0.87 1.04 0.12 0.022 0.12
C2CD4B rs11071657 0.68 0.63 1.03 0.09 0.008 0.06
SLC30A8 rs11558471 0.73 0.68 1.15 0.78 0.027 0.16
CRY2 rs11605924 0.49 0.49 1.04 0.14 0.015 0.09
ADCY5 rs11708067 0.76 0.78 1.12 0.57 0.027 0.15
SLC2A2 rs11920090 0.85 0.87 1.01 0.05 0.020 0.09
FADS1 rs174550 0.81 0.64 1.04 0.11 0.017 0.08
GCK rs1799884
a 0.15 0.16 1.07 0.20 0.062 0.43
DGK/TMEM195 rs2191349 0.60 0.52 1.06 0.25 0.030 0.22
PROX1 rs340874 0.59 0.52 1.07 0.32 0.013 0.08
G6PC2 rs560887
b 0.84 0.70 0.97 0.08 0.075 0.60
GLIS3 rs7034200 0.48 0.49 1.03 0.10 0.018 0.11
GCKR rs780094 0.73 0.62 1.06 0.21 0.029 0.18
TCF7L2 rs7903146
c 0.32 0.31 1.40 1.00 0.023 0.14
MADD rs7944584 0.78 0.75 1.01 0.05 0.021 0.11
RAF=risk (glucose-raising) allele frequency. Power was calculated using the South Asian RAF, the effect sizes reported in the MAGIC study [1], the sample sizes used in
each analysis, an additive model and a significance level (a) of 0.05. For the type 2 diabetes analyses power calculations, a disease prevalence of 10% was assumed. For
the fasting glucose analyses a population mean (SD) fasting glucose of 5.5 (0.6) mmol/l was used, as reported in Table 1.
aIn the current study the GCK rs1799884 SNP was used as a proxy for the rs4607517 variant reported in MAGIC (r
2=1.0 in CEU HapMap samples); the MAGIC RAF shown
is for rs4607517.
bFor the G6PC2 rs560887 SNP, the glucose-raising allele reduces the risk of type 2 diabetes (with nominal significance) in the MAGIC study. In this instance, to calculate
power for the type 2 diabetes analysis the minor allele frequency (0.16) and the inverse of the odds ratio (OR; 1.03) was used.
cThe RAF for the TCF7L2 rs7903146 SNP was not given in the MAGIC study; the RAF reported is for rs4506565 (r
2=0.92 between the two variants in MAGIC).
doi:10.1371/journal.pone.0024710.t003
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secretion. In addition, a SNP within the ADCY5 gene (rs9883204),
in LD with the variant investigated in this study, is associated with
foetal growth and birth weight [13]. Insulin is an important growth
factor in utero, potentially providing a common mechanism linking
reduced foetal growth with increased risk of type 2 diabetes. The
GLIS3 gene encodes the transcription factor GLIS family zinc
finger 3 isoform, a protein that regulates target gene transcription
and has been shown to play a key role in b-cell generation in mice
[14,15]. Rare functional mutations within the GLIS3 gene lead to a
syndrome of neonatal diabetes and congenital hyperthyroidism
[16], and the rs7020673 SNP within the gene is robustly associated
with type 1 diabetes [17]. The GLIS3 rs7034200 SNP only
displayed a weak association with type 2 diabetes in the MAGIC
study [1], although there is evidence that this variant confers risk
of the disease in a Chinese population [18]. As with the fasting
glucose analyses, some potential disparity was apparent between
our South Asian type 2 diabetes association results and those
reported by the MAGIC study [1] (Figure 2), although the
relatively small size of our cohort makes any differences difficult to
quantify statistically. It is interesting to note that, excluding the
TCF7L2 SNP, three of the four variants most strongly associated
with type 2 diabetes in the MAGIC study [1] (MTNR1B
rs10830963, PROX1 rs340874 and GCKR rs780094) have odds
ratios of less than one in our South Asian populations (Figure 2).
The lack of association of many of the studied variants with
fasting glucose and type 2 diabetes in our study cohort could be
due to small sample size and low statistical power (Table 3). For
the analysis of type 2 diabetes, this study had .80% power to
detect the effect of just the TCF7L2 SNP. The study was
underpowered to detect the effect of any SNP on fasting glucose
levels, assuming similar effect sizes to those seen in European
populations (Table 3). Although the statistical evidence for
heterogeneity is weak, it is also possible that the studied variants
have different effect sizes in our Punjabi populations compared
with Europeans. This may be due to differences in LD patterns
between the two ethnic groups, as disease-associated SNPs derived
from GWA studies are typically not aetiological variants. Previous
findings that the MTNR1B and G6PC2 variants genotyped in this
study are associated, either directly or through imputation, with
glucose levels in Indian Asians [9], however, make it unclear
whether any potential differences in LD patterns are likely to
contribute to our observed lack of association at these loci.
In conclusion, our study of Punjabi populations demonstrated
that 12 of 16 variants displayed b-values for fasting glucose with
the same direction of effect as that seen in Europeans. In addition,
we provide evidence that alleles of SNPs in ADCY5 and GLIS3 may
confer risk of type 2 diabetes, the first time that this has been
reported in South Asian populations.
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